Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35)
抗體來(lái)源（Source）
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) (SAD-S35) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 1.47 μg/mL using SARS-CoV-2 Inhibitor Screening Kit.Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.
克隆號(hào)（Clone）
AS35
亞型（Isotype）
Human IgG1 | Kappa
偶聯(lián)（Conjugate）
Unconjugated
抗體類型（Antibody Type）
Recombinant Monoclonal
種屬反應(yīng)性（Reactivity）
Virus
特異性（Specificity）
This product is a specific antibody against SARS-CoV-2 Spike protein RBD domain. No cross-reactivity is detected with Spike protein RBD domain of other coronaviruses, including SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1.
應(yīng)用（Application）
純度（Purity）
>95% as determined by SDS-PAGE.
純化（Purification）
Protein A purified / Protein G purified
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景（Background）
冠狀病毒可以通過與人ACE2受體相互作用感染人呼吸道上皮細(xì)胞。刺突蛋白是一種大的I型跨膜蛋白，含有兩個(gè)亞基S1和S2。S1主要包含一個(gè)受體結(jié)合結(jié)構(gòu)域（RBD），負(fù)責(zé)識(shí)別細(xì)胞表面受體。S2包含膜融合所需的基本元件。S蛋白在誘導(dǎo)中和抗體和T細(xì)胞反應(yīng)以及保護(hù)性免疫中起著關(guān)鍵作用。
關(guān)鍵字： Spike RBD;Spike RBD抗體;新冠病毒中和抗體;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國(guó)生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。